Please login to the form below

Aptalis

This page shows the latest Aptalis news and features for those working in and with pharma, biotech and healthcare.

HIV prevention pill heads July CHMP recommendations

Other positive recommendations were given for Aptalis' Truberzi (eluxadoline) as a treatment for irritable bowel syndrome with diarrhoea, along with two biosimilar versions of Sanofi's clot-busting drug Lovenox (enoxaparin) -

Latest news

Actavis claims top UK generics spot with Auden Mckenzie buy

Other acquisitions in the last 12 months have included $25bn for Forest Laboratories, $2.9bn for Aptalis, a $1.6bn deal for Furiex Pharma and $675m for Durata.
Forest Labs agrees $1.46bn deal to buy Furiex

Forest chief executive Brent Saunders said the Furiex deal "is a natural extension of our GI business following our $2.9bn acquisition of Aptalis earlier this year," adding that eluxadoline would
Forest said to be interested in $3bn Aptalis acquisition

The private equity group bought Aptalis for $1.3bn in 2008 and was looking to sell it on for $3bn-$4bn. ... The Aptalis rumour also comes shortly after Forest itself was the subject of speculation about a possible takeover by AstraZeneca.

More from news
Approximately 2 fully matching, plus 2 partially matching documents found.

Latest Intelligence

Pharma deals during February 2014

The announcement came just after Forest completed its acquisition of Aptalis last month for $3bn and this month sold a number of products to Hospira's Australian subsidiary Mayne Pharma for
Pharma deals during January 2014

Almost right to the end of the month, the big headline deal was that of Forest with its planned takeover of Aptalis. ... Aptalis itself was only formed in 2011 following the acquisition of Eurand by the Montreal based Axcan Pharma.
Deal Watch table for January 2014

4, 295. Aptalis/ Forest. Company acquisition. Acquiring sales turnover of $688m. 2, 900.

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Latest appointments

Intellia Therapeutics appoints Dr Moncef Slaoui and Dr Frank Verwiel

He has held numerous leadership roles including president and CEO of Aptalis Pharma prior to its acquisition by Forest Laboratories.
Lupin names chief corporate development officer

Theresa Stevens has experience at Novartis and Aptalis. Lupin has appointed Theresa Stevens as chief corporate development officer for its global operations. ... Stevens joins the India-based pharma company from Aptalis Pharma, where she was chief
Marino Garcia joins Synergy Pharmaceuticals

Garcia joins the New York-based gastrointestinal specialist from Aptalis Pharma, which also focused on the gastrointestinal market, as well as cystic fibrosis. ... Prior to his time at Aptalis Garcia was VP of US commercial operations and new product

More from appointments
Approximately 0 fully matching, plus 3 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company

claire@dovetailstrategies.com

About Dovetail We’re award-winning specialists in healthcare collaboration that makes patients’ lives better. Combining expertise with a passion for collaboration,...

Latest intelligence

InSite Mapping™ - a Novel Tool for Insight-gathering and Patient Journey Mapping: Learn how a client engaged 18 rheumatologist advisors over 6 months to create a patient journey map for SLE....
Alone we can do so little, together we can do so much: Collaboration is at the heart of successful patient engagement and effective healthcare provision. But in such a complex, nuanced network, true collaborations are rare. So how can we, as an...
7 important considerations for creating an inclusive clinical trial website: You might have noticed that all of us here at COUCH Health are big advocates for taking action to improve diversity and inclusion in the world of clinical research. ‘Taking...